The Subject Expert Committee (SEC), which advises the Central drug regulator on various matters of approval, has recommended grant of permission to Sanofi Healthcare India to import and market the drug olipudase alfa powder for use in paediatric and adult patients with waiver of local phase III and IV clinical trial in the country. The firm presented the proposal to the regulator seeking approval for import and marketing of olipudase alfa powder for concentrate for solution for infusion 20 mg vial indicated as enzyme replacement therapy for long-term treatment of noncentral nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in paediatric and adult patients with a request for waiver of phase III & phase IV clinical trial in the country. The committee noted that the drug falls under the orphan drug category and proposed indication is a rare disease. The SEC also noted that the drug has been granted
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!